Decoy Therapeutics Announced The Execution Of A Strategic Development Initiative Designed To Support The Advancement Of The Company's Designable Multi-antiviral Candidates Into Phase 1 First-in-human And Phase 2a Human Proof-of-concept Studies

뉴스 본문을 불러오고 있어요.

Decoy Therapeutics Announced The Execution Of A Strategic Development Initiative Designed To Support The Advancement Of The Company's Designable Multi-antiviral Candidates Into Phase 1 First-in-human And Phase 2a Human Proof-of-concept Studies | 웨이프 WAPE

Decoy Therapeutics Announced The Execution Of A Strategic Development Initiative Designed To Support The Advancement Of The Company's Designable Multi-antiviral Candidates Into Phase 1 First-in-human And Phase 2a Human Proof-of-concept Studies

기사 요약

관련 종목

댓글 —